Mesoblast Receives FDA BLA Filing Number for Rexlemestrocel-L in End-Stage Heart Failure
MESO sits 35% above its 52-week low of $10.32.
Summary
Mesoblast announced the FDA has accepted its Biologics License Application (BLA) for rexlemestrocel-L, a significant step towards potential approval for end-stage heart failure patients with LVADs.
Key Events · Product Development and Regulatory · MESO
-
BLA Filing Number Received
The FDA has provided a filing number for rexlemestrocel-L's Biologics License Application, indicating the application is complete and accepted for review.
-
Modular Review Requested
Mesoblast has requested a modular review process, which can streamline the FDA's assessment of the BLA.
-
Orphan Drug & RMAT Designations
Rexlemestrocel-L holds Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations, qualifying it for rolling and priority reviews, potentially accelerating the approval timeline.
-
Addresses High-Mortality Condition
The therapy targets life-threatening gastrointestinal bleeding in end-stage heart failure patients with LVADs, a population with high unmet medical need.
Analysis · MESO · Life Sciences
This filing marks a critical regulatory milestone for Mesoblast's rexlemestrocel-L, as the FDA has accepted its Biologics License Application for review. The drug's Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations suggest a potential for expedited and priority review, addressing a high-mortality condition in end-stage heart failure patients with LVADs. This moves the company closer to potential commercialization for a key pipeline asset.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 44% of the 972 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MESO was trading at $13.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $10.32 to $21.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.